Ivonescimab as first treatment for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (stage 3B, 3C, or 4) that can't be removed with surgery or treated with radiation and chemotherapy together.
- Your cancer tests positive for PD-L1 (a protein) and does not have certain gene changes (like EGFR or ALK).
- You have not had any prior cancer treatment for advanced disease, though you may have had treatment after surgery if it's been more than 6 months.
- You are at least 18 years old and in generally good health (able to care for yourself).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
Hear when a new Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.